ストックスクリーナーアプリを入手
7.3877
1.05%
0.0777
Bioventus Inc (BVS) 最新ニュース
Craig-Hallum Reiterates a Buy Rating on Bioventus (BVS), Sets a $15 PT - ca.finance.yahoo.com
Bioventus Inc.’s Price Action Aligns with Quant Signals [July 2025 Technicals]Free Growth-Oriented Investment Plans - 선데이타임즈
12 Best Medical Device Stocks to Buy According to Analysts - Insider Monkey
Bioventus at Canaccord Conference: Strategic Growth Path - Investing.com
Cantor Fitzgerald Reaffirms Their Buy Rating on Bioventus (BVS) - The Globe and Mail
Cantor Fitzgerald reiterates Overweight rating on Bioventus stock By Investing.com - Investing.com Canada
Bioventus (NASDAQ:BVS) Upgraded by Wall Street Zen to "Strong-Buy" Rating - MarketBeat
Bioventus Inc. Crosses 200 Day MA — Signal or NoiseTarget Return Focused Trade Insights Shared - metal.it
Bioventus Earnings Call: Strong Growth and Resilience - TipRanks
Should Investors Capitalize on Bioventus' Earnings Outperformance Amid Industry Lags? - AInvest
Bioventus Inc. Just Recorded A 154% EPS Beat: Here's What Analysts Are Forecasting Next - simplywall.st
Bioventus Inc. (NASDAQ:BVS) Q2 2025 Earnings Call Transcript - Insider Monkey
Bioventus outlines path to $100M+ PNS revenue opportunity as new products receive clearance - MSN
Bioventus Q2 Earnings Call: Robust Growth and Strategic Resilience - AInvest
Bioventus to Present at the Canaccord Genuity 45th Annual Global Growth Conference - The Manila Times
Craig-Hallum Maintains Bioventus(BVS.US) With Buy Rating, Announces Target Price $15 - 富途牛牛
Bioventus Second Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Bioventus Inc. Reports Q2 2025 Financial Results - TipRanks
Bioventus Inc. 2025 Q2ResultsEarnings Call Presentation (NASDAQ:BVS) - Seeking Alpha
Bioventus Q2 2025: Key Contradictions Unveiled on Tariffs, Growth Projections, and Market Dynamics - AInvest
Bioventus Q2 2025 slides: 6% organic growth despite revenue dip, FDA clearance boosts outlook By Investing.com - Investing.com South Africa
Bioventus Q2 2025 slides: 6% organic growth despite revenue dip, FDA clearance boosts outlook - Investing.com
Bioventus: Q2 Earnings Snapshot - The Washington Post
Transcript : Bioventus Inc., Q2 2025 Earnings Call, Aug 06, 2025 - MarketScreener
Earnings call transcript: Bioventus Q2 2025 sees steady EPS, revenue beat - Investing.com Canada
Earnings call transcript: Bioventus Q2 2025 sees steady EPS, revenue beat By Investing.com - Investing.com South Africa
Bioventus (BVS) Misses Q2 Earnings and Revenue Estimates - sharewise.com
Bioventus Inc. Provides Earnings Guidance for the Year 2025 - MarketScreener
Bioventus Inc Q2 2025 Earnings: Revenue Beats at $147.7M, EPS Mi - GuruFocus
Bioventus reports Q2 EPS 21c, consensus 20c - TipRanks
Bioventus Inc. SEC 10-Q Report - TradingView
Bioventus Q2 2025 swings to $0.11 EPS, trims debt with new 2030 loan | KAR SEC FilingForm 8-K - Stock Titan
Bioventus Reports Second Quarter Financial Results - TradingView
Bioventus earnings matched, revenue topped estimates By Investing.com - Investing.com Canada
Bioventus Q2 revenue dips 2.4%, organic growth 6.2% - MarketScreener
Bioventus Reports Second Quarter Financial Results | BVS Stock N - GuruFocus
Bioventus Q2 revenue down 2.4% YoY, EPS up 31%, cash ops up 71%. - AInvest
What To Expect From Bioventus Inc (BVS) Q2 2025 Earnings - GuruFocus
Bioventus enters into a new $400M credit agreement, lowering interest expenses - MSN
Bioventus Receives Positive Rating from Craig-Hallum, Analyst Maintains Buy Recommendation - AInvest
Bioventus Inc expected to post earnings of 21 cents a shareEarnings Preview - TradingView
Sector ETF Data Correlates with Strength in Bioventus Inc.Growth Based Investment Plan Guidance Highlighted - metal.it
Bioventus Secures $400 Million Credit Agreement - TipRanks
Bioventus secures $400mln credit agreement with lower interest margin. - AInvest
Bioventus Enters into a New $400 Million Senior Secured - GlobeNewswire
Bioventus Lands $400M Credit Deal: Saves $2M Annually with 75 BPS Rate Cut - Stock Titan
What is Bioventus Inc. company’s growth strategyExceptional market positioning - Jammu Links News
What are analysts’ price targets for Bioventus Inc. in the next 12 monthsExponential wealth increase - Jammu Links News
How does Bioventus Inc. compare to its industry peersInvest confidently with advanced analysis tools - Jammu Links News
How volatile is Bioventus Inc. stock compared to the marketBuild wealth faster with consistent growth stocks - Jammu Links News
Bioventus gets FDA nod for pain management devices - MSN
What institutional investors are buying Bioventus Inc. stockHigh-yield investments - Jammu Links News
How strong is Bioventus Inc. company’s balance sheetAchieve rapid wealth accumulation with smart picks - Jammu Links News
How does Bioventus Inc. generate profit in a changing economyUnlock expert insights for smarter investing - Jammu Links News
What are Bioventus Inc. company’s key revenue driversIdentify winners with top-tier analysis - Jammu Links News
Is Bioventus Inc. stock overvalued or undervaluedGet daily expert analysis for smarter investing - Jammu Links News
Should I hold or sell Bioventus Inc. stock in 2025Breakthrough capital growth - Jammu Links News
0.38%
1.22%
大文字化:
|
ボリューム (24 時間):